Bicycle Therapeutics PLC (NAS:BCYC)

$ 21.34 -0.37 (-1.7%) Market Cap: 812.48 Mil Enterprise Value: 413.39 Mil PE Ratio: 0 PB Ratio: 2.27 GF Score: 69/100

Bicycle Therapeutics PLC at TD Cowen Fall Oncology Innovation Summit (Virtual) Transcript
Nov 03, 2023
Bicycle Therapeutics PLC at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Bicycle Therapeutics PLC Corporate Call Transcript
Sep 11, 2023
Bicycle Therapeutics PLC at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Bicycle Therapeutics PLC at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
Bicycle Therapeutics PLC at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 01, 2022
Bicycle Therapeutics PLC at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Bicycle Therapeutics PLC at Jefferies London Healthcare Conference Transcript
Nov 17, 2022
Bicycle Therapeutics PLC at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Bicycle Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 13, 2022
Bicycle Therapeutics PLC at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021

Bicycle Therapeutics PLC at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022 / 02:30PM GMT

Release Date Price: $27.61 (+4.58%)

Transcript

Ted Tenthoff

Piper Sandler - Analyst

Good morning, everyone. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler, and thank you for joining us for this year's in-person Healthcare Conference.

Before I begin, I am required to point out certain disclosures regarding the relationship between Piper Sandler and Bicycle, our next presenting company, that are located at the back of the room and also at the registration desk. So Bicycle is developing a novel class of bi-cyclic peptides, aptly called Bicycles, to treat cancer and a range of other diseases. The company is in the clinic with multiple Bicycle Toxin Conjugates or BTCs. And now also tumor-targeted immune cell agonists or TICAs for immuno-oncology.

The company has partnerships with Genentech, Ionis, Oxurion, AstraZeneca. And here with us today is Chief Scientific Officer, Nick Keen; Chief Medical Officer, Dominic Smethurst; and also CFO, Lee Kalowski. Guys, thanks for being with us.

Questions & Answers

Ted Tenthoff

Piper Sandler - Analyst

So Nick, maybe you

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.